» Articles » PMID: 38265150

HNRNPA2B1 Promotes Oral Squamous Cell Carcinogenesis Via MA-dependent Stabilization of FOXQ1 MRNA Stability

Overview
Journal IUBMB Life
Date 2024 Jan 24
PMID 38265150
Authors
Affiliations
Soon will be listed here.
Abstract

Oral squamous cell carcinoma (OSCC), as a common type of oral malignancy, has an unclear pathogenesis. N methyladenosine (mA) is a reversible and dynamic process that participates in the modulation of cancer pathogenesis and development. As an mA recognition protein (reader), heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) show abnormally high expression in cancers. Forkhead box Q1 (FOXQ1), an oncogenic transcription factor, controls multiple biological processes (e.g., embryonic development, cell differentiation, and apoptosis, impacting the initiation and progression of cancers by mediating signaling pathways together with epithelial-mesenchymal transition). Through the Cancer Genome Atlas database screening along with clinical and laboratory experiments, in head and neck squamous cell carcinoma, we found a correlation between HNRNPA2B1 and FOXQ1 gene expression, with shared mA motifs between HNRNPA2B1 and FOXQ1 mRNA sequences. Silencing or overexpression of HNRNPA2B1 in OSCC cells affected the malignant phenotypes of OSCC cells in vitro, and depletion of HNRNPA2B1 retarded tumor growth in vivo. HNRNPA2B1 could bind to mA-modified FOXQ1 mRNA to enhance its mRNA stability, resulting in up-regulation of FOXQ1 protein expression. To conclude, HNRNPA2B1 was upregulated in OSCC and enhanced OSCC cell malignant phenotypes by stabilizing mA-modified FOXQ1 mRNA, eventually aggravating the malignancy and tumorigenicity of OSCC. This study accelerates the recognition of the potency of mA modification in OSCC and paves the path for OSCC's targeted diagnosis and therapy.

Citing Articles

The transcription factor FOXQ1 in cancer.

Koch S Cancer Metastasis Rev. 2025; 44(1):22.

PMID: 39777582 PMC: 11711781. DOI: 10.1007/s10555-025-10240-y.


N6-methyladenosine RNA modification in head and neck squamous cell carcinoma (HNSCC): current status and future insights.

Janakiraman P, Jayaprakash J, Muralidharan S, Narayan K, Khandelia P Med Oncol. 2024; 42(1):12.

PMID: 39580759 DOI: 10.1007/s12032-024-02566-4.


Role of N6-methyladenosine methylation in head and neck cancer and its regulation of innate immune pathways.

Cao L, Huang G, Fan J, Liu X, Ma Z Front Immunol. 2024; 15:1458884.

PMID: 39403369 PMC: 11471572. DOI: 10.3389/fimmu.2024.1458884.